Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MSC vs AT-MSC for Spinal Cord Injury
NCT02981576Phase 2Completed
- Sponsor
- University of Jordan
- Start
- Nov 2016
- Primary completion
- May 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous bone marrow derived mesenchymal stromal cells and JOINTSTEM in spinal cord injury (SCI) (2 arms), sponsored by University of Jordan. Primary endpoints: Number of Side Effects at 12 months and Improvement on ASIA Impairment Scale (AIS) at 12 months. Started Nov 2016; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cellsJOINTSTEM
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02981576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981576.